Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus.
Observational clinical research of COVID-19 patients can help clinicians better understand how the previously unknown SARS-CoV-2 virus acts, and findings from this research can better inform treatment and vaccine design.
This potential preventive treatment for Crohn’s disease was tested on a mouse model and on immune-reactive T cells from patients with Crohn’s disease.
Streptococcus pneumoniae is an opportunistic pathogen that commonly infects young children and the elderly. This atlas will help researchers better understand how to treat these infections.
Meier-Gorlin syndrome is a rare genetic developmental disorder that causes dwarfism, small ears, a small brain, missing patella and other skeletal abnormalities.
Further understanding is needed of the redox change called reductive stress and its impact on the onset and progression of neurodegeneration.
A local early-stage startup has been approved for low-cost, low-risk, non-invasive procedures for patients with chronic liver disease.
Mutations in CHD7 cause severe birth defects known as CHARGE syndrome cases, which include severe and life-threatening heart malformations.
Maryland-based Altimmune Inc. has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal candidate.
The company will focus on the invention, creation and monetization of proprietary medical technologies to solve major health challenges.
Page 5 of 39